Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for MPDL3280A

3 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCTHO1521

    10/16/2015

    A Phase III, Open-Label, Randomized, Study of MPDL3280A (Anti-PDL1 Antibody) Compared with Gemcitabine + Cisplatin or CARBOPLATIN for PD-L1-Selected, Chemotherapy Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer

    Treatment

    VICCTHO1519

    10/07/2015

    A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti−PDL1 Antibody) Compared with Cisplatin or Carboplatin+Pemetrexed for PD-L1−Selected Chemotherapy Naive Patients with Stage Iv Non-Squamous Non−Small Cell Lung Cancer

    Treatment

    VICCBRE1543

    09/30/2015

    A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti−PD-L1 Antibody) in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple -Negative Breast Cancer


    Print this page for your doctor